Abstract

Background: Allergoids are chemically modified allergens for specific immunotherapy. The clinical efficacy of commercially available allergoid products is hardly comparable to nonmodified allergens, because of their differing manufacturing methods, allergen compositions, therapy schemes and modifications, To ensure an evidence-based therapy, clinical efficacy of each allergoid should be proven by adequate clinical trials. Objective: To evaluate the clinical efficacy of available allergoid products in Germany for subcutaneous specific immunotherapy on the basis of the recommendations for clinical trials of the World Allergy Organization (WAO). Methods: A systematic literature search was conducted and the clinical efficacy was analysed according to the recommendations of the WAO. Results: 6 of 9 double-blind, placebo-controlled (DBPC) studies were included in the analysis. All trials were conducted with adults. A parallel literature search of German publications resulted in 2 DBPC studies. Clinical efficacy was documented for grass pollen allergoids in 3 studies with 3 products, and for mite allergoids in 2 studies with I product. Additionally, a German publication proved clinical efficacy in a DBPC study with a tree-allergoid preparation. There were no DBPC studies found for allergoid products with central European weeds. Moreover, studies showing long-term effects, prevention, carryover effects and studies in children were missing. Conclusion: Evidence of clinical efficacy, analysed according to the recommendations for clinical trials of the WAO, is limited to a few allergoid products and allergens.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.